Recently we showed that a pharmacological inhibition of MYCN through administration of a specific PNA (PNA-MYCN) is able to block rhabdomyosarcoma cell growth both in vitro and in vivo , without evidence of systemic toxicity [30]. The gene discussed is MYCN; the disease is rhabdomyosarcoma.